Stage-Specific Racial Disparities in Prostate Cancer Survival Outcomes.

Authors

Tsion Zewdu Minas, Eboneé Nicole Butler, Samuel Mwakisha Mwamburi, Tiffany H Dorsey, Deepa Bedi, Windy Dean-Colomb, Christopher A Loffredo, Stefan Ambs, Clayton Yates

Published in

The Prostate. Oct 06, 2026. Epub Oct 06, 2026.

Abstract

Racial disparities in prostate cancer (PCa) survival are inconsistently reported.
We evaluated long-term survival in 976 men from the NCI-Maryland PCa case-control study, stratified by disease stage.
There were no survival differences observed between African American (AA) and European American (EA) men with Stage 1 or 2 disease. In contrast, AA men with Stage 3 or 4 PCa experienced significantly higher prostate cancer-specific and all-cause mortality in equal-access Veterans Affairs (VA) and non-VA settings. Adjustment for baseline prostate-specific antigen (PSA) level, Gleason score, and treatment modalities attenuated but did not eliminate these differences.
Disparate survival outcomes for AA men with PCa emerge mainly at Stage 3 or 4 diagnosis, emphasizing the importance of early detection for these men. Notably, AA patients with advanced-stage disease were more likely to receive hormone therapy alone, a treatment pattern that may contribute to racial disparities in PCa survival.

PMID:
42837052
Bibliographic data and abstract were imported from PubMed on 07 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.